An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Professor Michael N. Hall from the Biozentrum, University of Basel, report in Nature that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
Advanced stage liver tumors may be safely treated through image-guided injections of an immunotherapy approved for melanoma, according to a study presented today at the Society of Interventional Radiology's Annual Scientific Meeting.
World meat consumption has increased during the last decades, and evidence is mounting that high consumption of red and mainly processed meat is unhealthy to humans and is related to chronic diseases such as cancer, type 2 diabetes, and cardiovascular disease. A new study published in the Journal of Hepatology adds non-alcoholic fatty liver disease (NAFLD) to the list.
A new report details three cases of secondary brain tumors in people with fibrolamellar hepatocellular carcinoma. The researchers say imaging tests could improve treatment for patients whose cancer spreads to the brain from the liver.
In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH). Now a study has found that empagliflozin, a newer treatment for type 2 diabetes, reduces liver fat in patients with NAFLD and diabetes. Results of the randomized controlled study, called the E-LIFT Trial, will be presented Monday at the Endocrine Society's 100th annual meeting in Chicago, Ill., during a late-breaking abstracts session.
Using e-cigarettes may lead to an accumulation of fat in the liver, a study of mice exposed to the devices suggests. The research will be presented Sunday, March 18, at ENDO 2018, the Endocrine Society's 100th annual meeting in Chicago, Ill.
The International Journal of Cancer has just published the results of an experimental therapy tested on mice. The research, led by the Signaling Lab research group of the UPV/EHU's Faculty of Medicine and Pharmacy and the Department of Pharmacology, Pharmacy and Pharmaceutical Technology of the University of Santiago de Compostela, achieved an 80 percent reduction in liver metastasis brought about by colon cancer.
A key cell process that could cause damage to bile ducts and help explain some liver diseases has been identified by scientists.
Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.
Bacteria found in the small intestines of mice and humans can travel to other organs and trigger an autoimmune response, according to a new Yale study. The researchers also found that the autoimmune reaction can be suppressed with an antibiotic or vaccine designed to target the bacteria, they said.